Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.

@article{Saito1990PhaseIS,
  title={Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.},
  author={Yashuo Saito and Kennichi Mori and Ken Tominaga and Kohhei Yokoi and Naoki Miyazawa},
  journal={Cancer chemotherapy and pharmacology},
  year={1990},
  volume={26 6},
  pages={389-92}
}
cis-Diamminedichloroplatinum(II) (CDDP) was given as a single agent at a dose of 25 mg/m2 daily for 5 days by continuous infusion; treatment was repeated every 4 weeks in 30 previously untreated patients with advanced non-small-cell lung cancer (NSCLC). The median age of the patients was 61 years; 13 patients had limited disease and 17, extensive disease. The overall response rate was 40% (12/30; 95% confidence limits, 23-58%), with a median survival of 8 months. Vomiting was observed in 37% of… CONTINUE READING